The National Cancer Institute (NCI) Working Group on chronic lymphocytic leukemia developed criteria for evaluating the response of patients with B-cell CLL to therapy.
Complete response - all of the following:
(1) physical examination of lymph nodes, liver and/or spleen: normal (no lymphadenopathy; spleen and liver not palpable)
(2) constitutional symptoms: none
(3) lymphocyte count <= 4,000 per µL
(4) neutrophil count >= 1,500 per µL
(5) platelet count > 100,000 per µL
(6) hemoglobin (untransfused) > 11 g/dL
(7) bone marrow examination: < 30% lymphocytes and no nodules; if marrow hypocellular repeat in 2 weeks
(8) duration of response >= 2 months
Partial response:
(1) physical examination of lymph nodes, liver and/or spleen: >= 50% decrease (if abnormal prior to treatment)
(2) lymphocyte count: >= 50% decrease in absolute count
(3) one or more of the following:
(3a) neutrophil count >= 1,500 per µL (in 1988 included 50% improvement)
(3b) platelet count > 100,000 per µL (in 1988 included 50% improvement)
(3c) hemoglobin (untransfused) > 11 g/dL
(3d) hemoglobin >= 50% improvement
(4) duration of response >= 2 months
Progressive disease - one or more of the following:
(1) physical examination of lymph nodes, liver and/or spleen: >= 50% increase, OR new
(2) circulating lymphocytes: >= 50% increase in absolute count
(3) development of Richter's syndrome
(4) development of prolymphocytic leukemia with > 55% prolymphocytes
Stable disease: all others (do not meet any of the above criteria)
Purpose: To evaluate the response to therapy of a patient with B-cell CLL using the NCI Working Group criteria.
Specialty: Hematology Oncology
Objective: response to therapy
ICD-10: C91.1,